Enveric Biosciences Inc (ENVB) Stock Price, Quote & News

Company Profile

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuro...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 444 8400

Website: www.enveric.com

Address:

245 First Street, Riverview II 18 th Floor, Cambridge, United States

Luckyjs38 May. 11 at 6:20 PM

$ENVB

0 · Reply

Luckyjs38 May. 11 at 3:10 PM

$ENVB $150+ incoming

1 · Reply

jacobmoney123 May. 10 at 12:45 PM

$ENVB get out while you can. It is a scam company. They have no product.

0 · Reply

Bill7835 May. 7 at 11:15 PM

$ENVB - about to get a lot of attention!

0 · Reply

patatechaude May. 6 at 5:22 PM

$ENVB Out at breakeven, not sure if I want to re-enter…

1 · Reply

Luckyjs38 May. 6 at 3:38 PM

$ENVB

1 · Reply

Luckyjs38 May. 6 at 2:34 PM

$ENVB I believe they will be awarded the government grant funding for ptsd treatment effective by the executive order

1 · Reply

Luckyjs38 May. 6 at 1:47 PM

$ENVB

0 · Reply

patatechaude May. 6 at 3:19 AM

$ENVB The good little pop today was easily killed. Not good. Stop in. Let’s see.

0 · Reply

Luckyjs38 May. 6 at 1:30 AM

$ENVB Please vote it’s very important ! You must hold shares at time of record date into the shareholder meeting to make them count. Don't get shaken out too much potential here with too much at stake. here are my votes

0 · Reply

Enveric Biosciences highlights preclinical data for EB-003

May 5, 2026, 8:00 AM EDT - 8 days ago

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

2026-04-30T19:26:43.000Z - 12 days ago

Enveric Biosciences trading resumes

2026-04-30T13:43:15.000Z - 12 days ago

Enveric Biosciences trading halted, volatility trading pause

Apr 28, 2026, 7:33 AM EDT - 15 days ago

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

LABT

2026-04-23T23:30:54.000Z - 19 days ago

Enveric Biosciences files to sell 6.82M shares of common stock

2026-04-21T17:19:08.000Z - 21 days ago

3 Penny Stocks to Watch Now, 4/21/26

PBM TOVX

Apr 21, 2026, 8:00 AM EDT - 22 days ago

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

Apr 20, 2026, 6:43 AM EDT - 23 days ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX GHRS HELP

Apr 17, 2026, 6:28 PM EDT - 25 days ago

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2026-04-17T00:05:12.000Z - 26 days ago

Enveric Biosciences prices $13.9M at-the-market offering

Apr 16, 2026, 8:00 PM EDT - 26 days ago

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2026-03-31T12:12:19.000Z - 6 weeks ago

Enveric Biosciences secures new U.S. patent for its EVM301 series

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Mar 27, 2026, 5:40 PM EDT - 6 weeks ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

2026-03-18T12:41:42.000Z - 7 weeks ago

Enveric Biosciences announces registration of five trademarks in Canada

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Announces Registration of Five Trademarks

2026-02-25T13:26:08.000Z - 2 months ago

Enveric Biosciences announces withdrawal of petition against patent

Feb 25, 2026, 8:00 AM EST - 2 months ago

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

2026-02-19T13:09:22.000Z - 2 months ago

Enveric Biosciences reports EB-003 receptor engagement assay data

Feb 19, 2026, 8:00 AM EST - 2 months ago

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

2026-02-10T11:22:55.000Z - 3 months ago

Enveric Biosciences files to sell 328,802 shares of common stock for holders

2026-01-29T13:21:43.000Z - 3 months ago

Enveric Biosciences expands agreement with Totec through license pact

Jan 29, 2026, 8:00 AM EST - 3 months ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 28, 2026, 5:00 PM EST - 3 months ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2026-01-28T13:16:27.000Z - 3 months ago

Enveric to sell 328,802 shares at $4.41 in registered direct offering

Jan 28, 2026, 8:00 AM EST - 3 months ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2025-12-29T13:10:17.000Z - 4 months ago

Enveric Biosciences announces issuance of U.S. patent

Dec 29, 2025, 8:00 AM EST - 4 months ago

Enveric Biosciences Announces Patent Issuance

Dec 12, 2025, 4:46 PM EST - 5 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 5 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 9, 2025, 8:00 AM EST - 5 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 4, 2025, 8:00 AM EST - 5 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Nov 26, 2025, 8:00 AM EST - 5 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 14, 2025, 4:05 PM EST - 6 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Oct 23, 2025, 8:00 AM EDT - 7 months ago

Enveric Biosciences Announces Reverse Stock Split

Oct 16, 2025, 8:30 AM EDT - 7 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 15, 2025, 8:00 AM EDT - 7 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 14, 2025, 9:00 AM EDT - 7 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 2, 2025, 8:45 AM EDT - 7 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Sep 18, 2025, 4:30 PM EDT - 8 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 8 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 8:00 AM EDT - 8 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 16, 2025, 8:45 AM EDT - 8 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 14, 2025, 8:00 AM EDT - 9 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Jul 23, 2025, 8:03 AM EDT - 10 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 15, 2025, 9:03 AM EDT - 10 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jun 24, 2025, 9:03 AM EDT - 11 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 16, 2025, 10:46 AM EDT - 11 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 10, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

May 28, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 20, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 14, 2025, 4:15 PM EDT - 1 year ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 17, 2025, 1:40 PM EDT - 1 year ago

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 6, 2025, 10:00 AM EST - 1 year ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Feb 27, 2025, 9:30 AM EST - 1 year ago

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 25, 2025, 1:30 PM EST - 1 year ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 4, 2025, 8:00 AM EST - 1 year ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 3, 2025, 5:00 PM EST - 1 year ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Luckyjs38 May. 11 at 6:20 PM

$ENVB

0 · Reply

Luckyjs38 May. 11 at 3:10 PM

$ENVB $150+ incoming

1 · Reply

jacobmoney123 May. 10 at 12:45 PM

$ENVB get out while you can. It is a scam company. They have no product.

0 · Reply

Bill7835 May. 7 at 11:15 PM

$ENVB - about to get a lot of attention!

0 · Reply

patatechaude May. 6 at 5:22 PM

$ENVB Out at breakeven, not sure if I want to re-enter…

1 · Reply

Luckyjs38 May. 6 at 3:38 PM

$ENVB

1 · Reply

Luckyjs38 May. 6 at 2:34 PM

$ENVB I believe they will be awarded the government grant funding for ptsd treatment effective by the executive order

1 · Reply

Luckyjs38 May. 6 at 1:47 PM

$ENVB

0 · Reply

patatechaude May. 6 at 3:19 AM

$ENVB The good little pop today was easily killed. Not good. Stop in. Let’s see.

0 · Reply

Luckyjs38 May. 6 at 1:30 AM

0 · Reply

Luckyjs38 May. 5 at 5:41 PM

$ENVB I have never been called before by a proxy solicitation company to ask how I’m voting. Someone’s scared …. Retail owns the float. Fulfill your fudiciary responsibilities to protect shareholder value. These are my votes . Please vote it’s extremely important we do not have another reverse split and no more shares available to dilute. It’s time you reward your long term shareholders I know what you hold and the value potential is in the billions in my opinion . Let’s see what happens 🔮🐦‍🔥♾️

2 · Reply